New drug cocktail aims to shrink Hard-to-Treat cancers

NCT ID NCT04644068

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. About 702 participants will receive the drug in different doses and combinations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD5305 (a PARP inhibitor drug taken by mouth)
What this could lead to: If successful, this could provide a new treatment option for people with advanced solid tumors that have limited options.
What could go wrong: This is an early-phase trial, so the drug may not work or could cause serious side effects. It is also testing many combinations, so results may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADDITIONAL INDICATIONS BELOW FOR MODULE 4 AND 5 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms breast cancer breast neoplasm cancer cervical cancer colorectal cancer colorectal neoplasm endometrial cancer endometrium neoplasm gastric cancer gastric neoplasm malignant pancreatic neoplasm non-small cell lung carcinoma ovarian cancer pancreatic neoplasm prostate cancer small cell lung carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADDITIONAL INDICATIONS BELOW FOR MODULE 4 AND 5 BILIARY CANCER BLADDER CANCER BREAST CANCER CERVICAL CANCER COLORECTAL CANCER ENDOMETRIAL CANCER GASTRIC CANCER NON-SMALL CELL LUNG CANCER OVARIAN CANCER PANCREATIC CANCER PROSTATE CANCER SMALL CELL LUNG CANCER ONLY IN MODULE 5

Contacts and locations

Locations

Research Site

Boston, Massachusetts, 02114, United States
Research Site

Boston, Massachusetts, 02215, United States
Research Site

New York, New York, 10021, United States
Research Site

Oklahoma City, Oklahoma, 73104, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Heidelberg, 3084, Australia
Research Site

Melbourne, 3000, Australia
Research Site

Vancouver, British Columbia, V5Z 1K1, Canada
Research Site

Toronto, Ontario, M5G 2M9, Canada
Research Site

Montreal, Quebec, H2X 0A9, Canada
Research Site

Montreal, Quebec, H3T 1E2, Canada
Research Site

Beijing, 100142, China
Research Site

Changchun, 130021, China
Research Site

Changsha, 410013, China
Research Site

Chengdu, 610041, China
Research Site

Chongqing, 400030, China
Research Site

Guangzhou, 510060, China
Research Site

Harbin, 150081, China
Research Site

Jining, 272029, China
Research Site

Shandong, China
Research Site

Shanghai, 200025, China
Research Site

Shanghai, 200032, China
Research Site

Taiyuan, 030001, China
Research Site

Wuhan, 430079, China
Research Site

Xi'an, 710061, China
Research Site

Brno, 656 53, Czechia
Research Site

Prague, 15006, Czechia
Research Site

Budapest, 1062, Hungary
Research Site

Budapest, 1082, Hungary
Research Site

Budapest, 1122, Hungary
Research Site

Milan, 20132, Italy
Research Site

Milan, 20141, Italy
Research Site

Modena, 41125, Italy
Research Site

Naples, 80131, Italy
Research Site

Padova, 35128, Italy
Research Site

Roma, 00168, Italy
Research Site

Chūōku, 104-0045, Japan
Research Site

Kōtoku, 135-8550, Japan
Research Site

Bydgoszcz, 85-796, Poland
Research Site

Gdansk, 80-214, Poland
Research Site

Gdynia, 81-519, Poland
Research Site

Grzepnica, 72-003, Poland
Research Site

Lodz, 90-302, Poland
Research Site

Torun, 87-100, Poland
Research Site

Warsaw, 02-781, Poland
Research Site

Moscow, 111123, Russia
Research Site

Moscow, 115478, Russia
Research Site

Moscow, 117997, Russia
Research Site

Moscow, 143442, Russia
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Barcelona, 08035, Spain
Research Site

Madrid, 28040, Spain
Research Site

Madrid, 28041, Spain
Research Site

Madrid, 28050, Spain
Research Site

Málaga, 29010, Spain
Research Site

Pozuelo de Alarcón, 28223, Spain
Research Site

Seville, 41013, Spain
Research Site

Chernivtsі, 58013, Ukraine
Research Site

Ivano-Frankivsk, 76018, Ukraine
Research Site

Kyiv, 03022, Ukraine
Research Site

Uzhhorod, 88000, Ukraine
Research Site

Cambridge, CB2 0QQ, United Kingdom
Research Site

Manchester, M20 4BX, United Kingdom
Research Site

Oxford, OX3 7LE, United Kingdom
Research Site

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.